EXTENSION STUDY EVALUATING TREATMENT WITH PF-05280586 VERSUS RITUXIMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE PARTICIPATED IN OTHER PF-05280586 CLINICAL TRIALS
EXTENSION STUDY EVALUATING TREATMENT WITH PF-05280586 VERSUS RITUXIMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE PARTICIPATED IN OTHER PF-05280586 CLINICAL TRIALS
This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US or rituximab-EU to rituximab-Pfizer. This study will provide continued treatment access to subjects with active rheumatoid arthritis who have participated for at least 16 weeks in other studies in the rituximab Pfizer program.
Inclusion Criteria:
Exclusion Criteria:
Tampa, Florida 33612, United States
Great Neck, New York 11021, United States
Barranquilla, Atlántico, Colombia
San Luis Potosà City, 78213, Mexico
Kemerovo, 650000, Russia
Saint Petersburg, 190068, Russia
Samara, 443095, Russia
Samara, 443095, Russia
KwaZulu Natal, 3000, South Africa